GALIBRA NEUROSCIENCE
Galibra Neuroscience develops gene-based therapies targeting GABA-related genetic disorders, which cause developmental delay, autism, and epilepsy in pediatric patients. The company pursues gene replacement and gene editing approaches across over 20 GABA pathway genes, leveraging partnerships with academic institutes and patient advocacy groups to advance disease-modifying treatments from research toward clinical evaluation.
- Drug Discovery & Therapeutics
- Biotechnology
- Healthcare Technology
Funding
Founders
Founder details are not available yet.
Product
Problem
Variants in over 20 genes involved in GABA synthesis, neurotransmission, degradation, and re-uptake lead to GABA imbalance, which is the root cause of many rare pediatric disorders. These disorders share common clinical manifestations including developmental delay, autism, and epilepsy, and currently lack disease-modifying treatments.
Solution
Galibra Neuroscience develops gene therapies designed to restore GABA balance in patients with GABA-related genetic disorders. The company's approach uses gene replacement therapy and gene editing techniques to target the specific genes responsible for GABA dysregulation. By precisely addressing the underlying genetic cause, the therapies aim to achieve functional GABA balance and provide disease-modifying benefits. The company collaborates with leading academic institutes and patient advocacy groups to streamline the translation of these novel therapies from bench to bedside.
Target Audience
Primary customers are pediatric patients with rare genetic GABA disorders and the healthcare providers and clinical research organizations treating them, as well as patient advocacy groups supporting these communities.
Features
- Gene replacement therapy and gene editing platforms targeting over 20 GABA-related genes
- Focus on rare pediatric disorders with shared clinical manifestations including developmental delay, autism, and epilepsy
- Precision medicine approach based on known gene function and location in GABA pathways
- Partnerships with academic institutions and patient advocacy groups to accelerate clinical development
- Research spans both monogenic rare disorders and broader neurological conditions